14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $36.78 $42.85 Wednesday, 24th Apr 2024 CLDX stock ended at $37.02. This is 1.99% less than the trading day before Tuesday, 23rd Apr 2024. During the day the stock fluctuated 2.53% from a day low at $36.96 to a day high of $37.90.
90 days $34.65 $53.18
52 weeks $22.11 $53.18

Historical Celldex Therapeutics prices

Date Open High Low Close Volume
Apr 24, 2024 $37.87 $37.90 $36.96 $37.02 347 967
Apr 23, 2024 $38.91 $39.67 $37.62 $37.77 418 705
Apr 22, 2024 $38.50 $39.40 $37.99 $38.85 530 129
Apr 19, 2024 $38.24 $38.47 $36.78 $37.98 588 991
Apr 18, 2024 $39.41 $39.80 $38.31 $38.53 536 448
Apr 17, 2024 $39.01 $40.45 $38.67 $39.63 889 388
Apr 16, 2024 $39.03 $39.27 $38.15 $38.60 614 796
Apr 15, 2024 $39.44 $40.12 $38.69 $39.07 322 670
Apr 12, 2024 $40.53 $40.83 $38.56 $39.25 483 232
Apr 11, 2024 $39.63 $41.67 $39.03 $40.87 537 466
Apr 10, 2024 $39.33 $39.44 $38.10 $39.19 746 547
Apr 09, 2024 $39.75 $40.66 $39.40 $40.62 439 222
Apr 08, 2024 $39.89 $39.89 $38.89 $39.74 291 673
Apr 05, 2024 $39.01 $40.61 $38.55 $39.58 474 200
Apr 04, 2024 $40.83 $41.49 $39.44 $39.57 588 294
Apr 03, 2024 $40.73 $41.67 $40.10 $40.35 717 395
Apr 02, 2024 $40.65 $41.37 $40.07 $41.16 1 100 460
Apr 01, 2024 $41.84 $41.84 $40.53 $41.64 629 132
Mar 28, 2024 $41.68 $42.19 $41.25 $41.97 510 304
Mar 27, 2024 $41.33 $42.36 $40.66 $41.79 468 141
Mar 26, 2024 $41.64 $41.85 $40.42 $41.04 466 926
Mar 25, 2024 $41.94 $42.85 $41.26 $41.44 710 711
Mar 22, 2024 $41.63 $42.29 $40.98 $41.99 659 657
Mar 21, 2024 $42.71 $43.42 $40.93 $41.01 819 847
Mar 20, 2024 $40.08 $42.33 $39.51 $42.15 787 352
Click to get the best stock tips daily for free!

About Celldex Therapeutics

Celldex Therapeutics Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity... CLDX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT